ticlopidine has been researched along with Embolism, Pulmonary in 17 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antithrombotic effect of Danggui and Honghua, herbs commonly used in Traditional Chinese medicine to treat the syndrome corresponding to vascular thrombosis, and their potential interactions with clopidogrel were investigated." | 3.76 | Antithrombotic effects of Danggui, Honghua and potential drug interaction with clopidogrel. ( Li, Y; Wang, N, 2010) |
| "ESSENTIALS: Cancer patients have a high rate of venous thrombosis (VT) but the underlying mechanisms are unknown." | 1.43 | Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. ( Bergmeier, W; Boulaftali, Y; Cooley, BC; Dee, R; Fuentes, R; Geddings, JE; Getz, TM; Hisada, Y; Key, NS; Mackman, N; Whelihan, M; Wolberg, AS, 2016) |
| "Clinically symptomatic deep venous thrombosis was detected in association with four (0." | 1.34 | Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. ( Boutary, M; Dorr, LD; Gendelman, V; Long, WT; Maheshwari, AV; Wan, Z, 2007) |
| "Treatment with ticlopidine resulted in a favorable course." | 1.30 | [Pulmonary infarction diagnosed by transbronchial lung biopsy]. ( Doi, H; Muguruma, H; Nakayama, T; Nii, E; Terasawa, M, 1999) |
| " Combination therapy of anti-platelet aggregating agents such as phthalazinol, dipyridamole, ticlopidine and indomethacin suppressed these toxic changes." | 1.28 | [Effects of anti-platelet aggregating agents on peplomycin induced pulmonary toxicity in mice]. ( Ekimoto, H; Ito, J; Okada, M; Takahashi, K, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.76) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamamoto, K | 1 |
| Fujita, M | 1 |
| Tabashi, K | 1 |
| Kawashima, Y | 1 |
| Kato, E | 1 |
| Oya, M | 1 |
| Iso, T | 1 |
| Iwao, J | 1 |
| Kalinin, AA | 1 |
| Patlachuk, MV | 1 |
| Morozov, SP | 1 |
| Nosenko, EM | 1 |
| Sal'nikov, PS | 1 |
| Lawall, H | 1 |
| Oberacker, R | 1 |
| Zemmrich, C | 1 |
| Bramlage, P | 1 |
| Diehm, C | 1 |
| Schellong, SM | 1 |
| Geddings, JE | 1 |
| Hisada, Y | 1 |
| Boulaftali, Y | 1 |
| Getz, TM | 1 |
| Whelihan, M | 1 |
| Fuentes, R | 1 |
| Dee, R | 1 |
| Cooley, BC | 1 |
| Key, NS | 1 |
| Wolberg, AS | 1 |
| Bergmeier, W | 1 |
| Mackman, N | 1 |
| Windecker, S | 1 |
| Tijssen, J | 1 |
| Giustino, G | 1 |
| Guimarães, AH | 1 |
| Mehran, R | 1 |
| Valgimigli, M | 1 |
| Vranckx, P | 1 |
| Welsh, RC | 1 |
| Baber, U | 1 |
| van Es, GA | 1 |
| Wildgoose, P | 1 |
| Volkl, AA | 1 |
| Zazula, A | 1 |
| Thomitzek, K | 1 |
| Hemmrich, M | 1 |
| Dangas, GD | 1 |
| Kim, S | 1 |
| Yun, YM | 1 |
| Chae, HJ | 1 |
| Cho, HJ | 1 |
| Ji, M | 1 |
| Kim, IS | 1 |
| Wee, KA | 1 |
| Lee, W | 1 |
| Song, SH | 1 |
| Woo, HI | 1 |
| Lee, SY | 1 |
| Chun, S | 1 |
| Li, Y | 1 |
| Wang, N | 1 |
| Gentilomo, C | 1 |
| Huang, YS | 1 |
| Raffini, L | 1 |
| Khemasuwan, D | 1 |
| Chae, YK | 1 |
| Gupta, S | 1 |
| Carpio, A | 1 |
| Yun, JH | 1 |
| Neagu, S | 1 |
| Lucca, AB | 1 |
| Valsecchi, ME | 1 |
| Mora, JI | 1 |
| Sobieszczyk, P | 1 |
| Fishbein, MC | 1 |
| Goldhaber, SZ | 1 |
| Hankey, GJ | 1 |
| Eikelboom, JW | 1 |
| Momi, S | 1 |
| Pitchford, SC | 1 |
| Alberti, PF | 1 |
| Minuz, P | 1 |
| Del Soldato, P | 1 |
| Gresele, P | 1 |
| Hylands, R | 1 |
| Dorr, LD | 1 |
| Gendelman, V | 1 |
| Maheshwari, AV | 1 |
| Boutary, M | 1 |
| Wan, Z | 1 |
| Long, WT | 1 |
| Doi, H | 1 |
| Nii, E | 1 |
| Muguruma, H | 1 |
| Nakayama, T | 1 |
| Terasawa, M | 1 |
| Tufano, A | 1 |
| Cerbone, AM | 1 |
| Di Minno, G | 1 |
| Okada, M | 1 |
| Ekimoto, H | 1 |
| Ito, J | 1 |
| Takahashi, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes[NCT02556203] | Phase 3 | 1,653 participants (Actual) | Interventional | 2015-12-16 | Terminated (stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 83 |
| Antiplatelet | 68 |
Composite of BARC 2,3 or 5 bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 148 |
| Antiplatelet | 85 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 14 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 68 |
| Antiplatelet | 63 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 105 |
| Antiplatelet | 78 |
ISTH major bleeds (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 49 |
| Antiplatelet | 30 |
The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 137 |
| Antiplatelet | 100 |
PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 46 |
| Antiplatelet | 31 |
Composite of TIMI major and minor bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 42 |
| Antiplatelet | 24 |
1 review available for ticlopidine and Embolism, Pulmonary
| Article | Year |
|---|---|
The use of antithrombotic drugs in older people.
Topics: Aged; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Myo | 2002 |
1 trial available for ticlopidine and Embolism, Pulmonary
15 other studies available for ticlopidine and Embolism, Pulmonary
| Article | Year |
|---|---|
Novel calcium antagonists. Synthesis and structure-activity relationship studies of benzothiazoline derivatives.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Chemical Phenomena; Chemistry; Guinea Pigs; Heart | 1988 |
[The staged treatment of popliteal, ileal and femoral arteries aneurisms].
Topics: Aneurysm; Clopidogrel; Combined Modality Therapy; Femoral Artery; Humans; Iliac Artery; Male; Middle | 2013 |
Prevalence of deep vein thrombosis in acutely admitted ambulatory non-surgical intensive care unit patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; APACHE; Aspirin; Clopidogrel; Female; Fibrin Fibrinogen Deg | 2014 |
Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice.
Topics: Adenocarcinoma; Animals; Blood Platelets; Cell Line, Tumor; Cell-Derived Microparticles; Clopidogrel | 2016 |
Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.
Topics: Anticoagulants; Antidepressive Agents; Antimetabolites, Antineoplastic; Antitubercular Agents; Aryla | 2017 |
Antithrombotic effects of Danggui, Honghua and potential drug interaction with clopidogrel.
Topics: Animals; Bleeding Time; Carthamus tinctorius; Clopidogrel; Drug Interactions; Drugs, Chinese Herbal; | 2010 |
Significant increase in clopidogrel use across U.S. children's hospitals.
Topics: Adolescent; Child; Child, Preschool; Clopidogrel; Coronary Thrombosis; Databases, Factual; Drug Ther | 2011 |
Dose-related effect of statins in venous thrombosis risk reduction.
Topics: Aged; Aspirin; Atherosclerosis; Cerebral Infarction; Clopidogrel; Cohort Studies; Cross-Sectional St | 2011 |
Acute pulmonary embolism: don't ignore the platelet.
Topics: Acute Disease; Animals; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidog | 2002 |
Antiplatelet drugs.
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein G | 2003 |
Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice.
Topics: Animals; Aspirin; Blood Coagulation Tests; Clopidogrel; Disease Models, Animal; Drug Therapy, Combin | 2005 |
Pulmonary thromboembolism.
Topics: Animals; Cat Diseases; Cats; Clopidogrel; Diagnosis, Differential; Female; Fibrinolytic Agents; Hepa | 2006 |
Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2007 |
[Pulmonary infarction diagnosed by transbronchial lung biopsy].
Topics: Adult; Biopsy; Bronchoscopy; Fibrinolytic Agents; Humans; Lung; Male; Pulmonary Embolism; Ticlopidin | 1999 |
[Effects of anti-platelet aggregating agents on peplomycin induced pulmonary toxicity in mice].
Topics: Animals; Bleomycin; Lung Diseases; Male; Mice; Mice, Inbred ICR; Peplomycin; Platelet Aggregation In | 1989 |